Full Product Name
DYSF siRNA (Mouse)
Product Synonym Names
FER1L1; Dysferlin; Dystrophy-associated fer-1-like protein; Fer-1-like protein 1
Product Gene Name
DYSF sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9ESD7
Specificity
DYSF siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse DYSF gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DYSF sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DYSF sirna
siRNA to inhibit DYSF expression using RNA interference
Applications Tested/Suitable for DYSF sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DYSF. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001071162.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001077694.2
[Other Products]
UniProt Primary Accession #
Q9ESD7
[Other Products]
UniProt Secondary Accession #
Q6KAR3; Q80VT0; Q9QXC0[Other Products]
UniProt Related Accession #
Q9ESD7[Other Products]
Molecular Weight
235,908 Da
NCBI Official Full Name
dysferlin isoform 2
NCBI Official Synonym Full Names
dysferlin
NCBI Official Symbol
Dysf??[Similar Products]
NCBI Official Synonym Symbols
D6Pas3; AI604795; 2310004N10Rik
??[Similar Products]
NCBI Protein Information
dysferlin
UniProt Protein Name
Dysferlin
UniProt Synonym Protein Names
Dystrophy-associated fer-1-like protein; Fer-1-like protein 1
UniProt Gene Name
Dysf??[Similar Products]
UniProt Synonym Gene Names
Fer1l1??[Similar Products]
UniProt Entry Name
DYSF_MOUSE
UniProt Comments for DYSF
DYSF: Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress. Defects in DYSF are the cause of limb-girdle muscular dystrophy type 2B (LGMD2B). LGMD2B is an autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs. Defects in DYSF are the cause of Miyoshi muscular dystrophy type 1 (MMD1). MMD1 is a late-onset muscular dystrophy involving the distal lower limb musculature. It is characterized by weakness that initially affects the gastrocnemius muscle during early *****hood. Otherwise the phenotype overlaps with LGMD2B, especially in age at onset and creatine kinase elevation. Defects in DYSF are the cause of distal myopathy with anterior tibial onset (DMAT). Onset of the disorder is between 14 and 28 years of age and the anterior tibial muscles are the first muscle group to be involved. Inheritance is autosomal recessive. Belongs to the ferlin family. 15 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Calcium-binding; Vesicle
Cellular Component: membrane; lamellipodium; endocytic vesicle; cytoplasm; T-tubule; early endosome; late endosome; integral to membrane; plasma membrane; cytoplasmic vesicle; endosome; sarcolemma
Molecular Function: protein binding; calcium-dependent phospholipid binding; metal ion binding; phospholipid binding; calcium ion binding; lipid binding
Biological Process: vesicle fusion; plasma membrane repair
Research Articles on DYSF
1. results show that dysferlin exerts protective effects on the fukutin(Hp/-) FCMD mouse model, and the (dysferlin(sjl/sjl): fukutin(Hp/-)) mice will be useful as a novel model for a recently proposed antisense oligonucleotide therapy for FCMD
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
